PDCD1 and metabolic dysfunction-associated steatotic liver disease: The genetic or pharmacological blockade of METTL3 plus anti-PD-1 shows promising efficacy against NAFLD-HCC in vivo, emphasizing METTL3 as a potential therapeutic target for NAFLD-HCC treatment.